Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5

SARS-CoV-2 Omicron variant XBB.1.5 has shown extraordinary immune escape even for fully vaccinated individuals. There are currently no approved antibodies that neutralize this variant, and continued emergence of new variants puts immunocompromised and elderly patients at high risk. Rapid and cost-ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Entzminger, Kevin C, Fleming, Jonathan K, Entzminger, Paul D, Espinosa, Lisa Yuko, Samadi, Alex, Hiramoto, Yuko, Okumura, Shigeru C J, Maruyama, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262839/
https://www.ncbi.nlm.nih.gov/pubmed/37324547
http://dx.doi.org/10.1093/abt/tbad006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262839/
https://www.ncbi.nlm.nih.gov/pubmed/37324547
http://dx.doi.org/10.1093/abt/tbad006

Ejemplares similares